| Literature DB >> 30508378 |
Abstract
Nanoscience has long been lauded as a method through which tumor-associated barriers could be overcome. As successful as cancer immunotherapy has been, limitations associated with the tumor microenvironment or side effects of systemic treatment have become more apparent. In this Review, we seek to lay out the therapeutic challenges associated with the tumor microenvironment and the ways in which nanoscience is being applied to remodel the tumor microenvironment and increase the susceptibility of many cancer types to immunotherapy. We detail the nanomedicines on the cutting edge of cancer immunotherapy and how their interactions with the tumor microenvironment make them more effective than systemically administered immunotherapies.Entities:
Keywords: cancer; checkpoint inhibitors; cytokines; cytotoxic T cells; immunogenic cell death; immunotherapy; nanoparticles; nanovaccine; tumor microenvironment
Mesh:
Substances:
Year: 2018 PMID: 30508378 DOI: 10.1021/acsnano.8b05893
Source DB: PubMed Journal: ACS Nano ISSN: 1936-0851 Impact factor: 15.881